CLINICAL TRIALS PROFILE FOR SPORANOX
✉ Email this page to a colleague
All Clinical Trials for SPORANOX
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00356915 ↗ | Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail. | Completed | GlaxoSmithKline | Phase 3 | 2006-07-01 | Onychomycosis is a common condition accounting for approximately half of all nail disorders. It is most commonly caused by dermatophytes. Itraconazole has been approved for the treatment of onychomycosis in the United States with an approved dosage regimen for the treatment of onychomycosis of the toenail of once daily (QD) treatment with 200mg of itraconazole (two 100 mg capsules) for 12 weeks. Barrier Therapeutics has developed a 200 mg tablet which could be used in a more convenient one-tablet-per-day dosing regimen. This clinical trial will compare the efficacy and safety of this new tablet formulation with itraconazole capsules and placebo. |
| NCT00356915 ↗ | Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail. | Completed | Stiefel, a GSK Company | Phase 3 | 2006-07-01 | Onychomycosis is a common condition accounting for approximately half of all nail disorders. It is most commonly caused by dermatophytes. Itraconazole has been approved for the treatment of onychomycosis in the United States with an approved dosage regimen for the treatment of onychomycosis of the toenail of once daily (QD) treatment with 200mg of itraconazole (two 100 mg capsules) for 12 weeks. Barrier Therapeutics has developed a 200 mg tablet which could be used in a more convenient one-tablet-per-day dosing regimen. This clinical trial will compare the efficacy and safety of this new tablet formulation with itraconazole capsules and placebo. |
| NCT00588016 ↗ | Concentration of Itraconazole Solution in Nasal Secretions | Completed | Mayo Clinic | Phase 1 | 2007-04-01 | The primary objective of this study is to determine the concentration of itraconazole irrigation in nasal mucous specimens via collection and High-performance liquid chromatography (HPLC) assay. Eight (8) patients with chronic rhinosinusitis (CRS) and two (2) healthy controls will be enrolled in the initial evaluation. After an initial control nasal specimen, followed by seven days of twice daily topical itraconazole irrigation, nasal specimens will be collected at varying time intervals and the concentrations measured. The primary endpoint is development of a reliable collection and assay technique with concentration curves over time of topically administered itraconazole. A secondary endpoint is to determine if the concentrations measured achieve a mean inhibitory concentration (MIC90) to commonly cultured fungal species in the nose. |
| NCT00769600 ↗ | Phase II Study of Itraconazole and Pemetrexed in Patients With Previously Treated Non-Squamous NSCLC | Terminated | Sidney Kimmel Comprehensive Cancer Center | Phase 2 | 2008-11-01 | Primary Objective To evaluate the 3-month event-free survival of the combination of the combination of itraconazole and pemetrexed in patients with recurrent/refractory non-small cell lung cancer. Secondary Objectives To determine the objective response rate of the combination of itraconazole and pemetrexed in patients with recurrent/refractory non-small cell lung cancer. |
| NCT00769600 ↗ | Phase II Study of Itraconazole and Pemetrexed in Patients With Previously Treated Non-Squamous NSCLC | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 | 2008-11-01 | Primary Objective To evaluate the 3-month event-free survival of the combination of the combination of itraconazole and pemetrexed in patients with recurrent/refractory non-small cell lung cancer. Secondary Objectives To determine the objective response rate of the combination of itraconazole and pemetrexed in patients with recurrent/refractory non-small cell lung cancer. |
| NCT00787917 ↗ | An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA) | Terminated | Novartis Pharmaceuticals | Phase 4 | 2008-11-01 | This study will evaluate the safety and efficacy of omalizumab for the treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in patients with Cystic Fibrosis aged 12 years and older. |
| NCT00789113 ↗ | Determination of Absorption and Elimination of Lamotrigine-XR | Completed | GlaxoSmithKline | Phase 1/Phase 2 | 2008-11-01 | People over 65 years of ag break down (metabolize) drugs differently than younger adults. It is not known why this happens or how elderly people absorb or break down these drug differently. These difference may show that elderly individuals need lower doses of medications to avoid possible toxicity. We are interested in studying how yor body absorbs and breaks down your lamotrigine medication. This research may indicate that doses of lamotrigine should be lowered as people get older. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SPORANOX
Condition Name
Clinical Trial Locations for SPORANOX
Trials by Country
Clinical Trial Progress for SPORANOX
Clinical Trial Phase
Clinical Trial Sponsors for SPORANOX
Sponsor Name
